Search PubMed⌕ Search

Biomedical subjects

P Schellhammer

Publications and source records attributed to P Schellhammer.

25 records · Page 2Linked to original sources
PubMed1995

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

OBJECTIVES: To compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer. METHODS: Randomized, double-blind (for antiandrogen therapy), multicenter study with a 2 x 2 factorial design. Eight hundred thirteen patients were allocated 1:1 to bicalutamide (50 mg once daily) and flutamide (250 mg three times daily) and 2:1 to goserelin acetate (3.6 mg every 28 days) and leuprolide acetate (7.5 mg every 28 days). RESULTS: With a median duration of follow-up of 49 weeks, time to treatment failure, the primary endpoint, was significantly (P = 0.005) better for the bicalutamide plus LHRH-A group than for the flutamide plus LHRH-A group. Patients in the flutamide plus LHRH-A group were 34% more likely to fail treatment over the given time period, as indicated by the hazard ratio of 0.749 (95% confidence interval, 0.61 to 0.92) for bicalutamide plus LHRH-A to flutamide plus LHRH-A. Results for secondary endpoints (survival, quality of life, and subjective response) were similar between groups. Diarrhea occurred in 24% of patients in the flutamide plus LHRH-A group, compared with 10% of patients in the bicalutamide plus LHRH-A group (P < 0.001). CONCLUSIONS: In patients with metastatic prostate cancer, bicalutamide plus LHRH-A is well tolerated and provides superior efficacy to flutamide plus LHRH-A with respect to time to treatment failure. Assessment of the effects of these regimens on longer term survival requires additional time for follow-up.

Adenocarcinoma↗
PubMed1992

Locoregional disease.

Explore the source record for details and available documents.

Combined Modality Therapy↗
PubMed1992

The significance of post-irradiation prostate biopsy with long-term follow-up.

Ninety-four patients, Stage A2-C, definitively irradiated for adenocarcinoma of the prostate from 1975 to 1981 underwent digitally directed transperineal needle biopsy of a clinically negative prostate gland at least 18 months post-therapy. Ten of 55 patients (18%) treated with Iodine-125 implantation and 7 of 39 patients (18%) externally irradiated were found to have positive biopsy specimens. Overall, clinical local failure occurred in 53% of patients with positive biopsy results but in only 18% with negative specimens, p = .006. The false negative biopsy rate in patients treated with I-125 was nearly three times that for external beam, 24% versus 9%, perhaps because of the greater possibility of inhomogeneous dose distribution with I-125, allowing for a higher degree of sampling error. Actuarial local failure at 5 years was 44% versus 8% with positive and negative biopsies, respectively, and 75% versus 24% at 10 years (p = .0001). The distant metastatic rate was twice as high in biopsy-positive as compared to biopsy-negative patients, 71% versus 35%, p = .015. Actuarially, only 19% of patients with a positive biopsy are NED at 10 years as compared to 62% of those with a negative biopsy (p = .0001). PSA values are supportive in those patients thought to be disease-free. The incidence of positive biopsy and associated local recurrence are in keeping with clinical treatment failure rates as reported in multiple studies to date.

Adenocarcinoma↗
PubMed1984

Management of bleeding renal angiomyolipomas by transcatheter embolization following CT diagnosis.

Renal angiomyolipomas are commonly associated with spontaneous hemorrhage which can be life-threatening and may require radical nephrectomy for control of hemorrhage. Transcatheter embolization was used in 2 cases of spontaneously bleeding angiomyolipomas; permanent control was achieved in 1 case and temporary control in the other. This more conservative approach was made possible by our ability to diagnose these benign renal tumors confidently using computed tomography.

Aged↗
PubMed1976

The use of spermatic cord lymphatics in the relief of surgically created lower extremity edema. A preliminary report of experiments in dogs.

When lower extremity lymphedema is not amenable to control by medical methods, attempts to ameliorate the problem surgically have generally been unsatisfactory. The intact testis and spermatic cord provide a potential bridge that may permit communication between the unobstructed lymphatics of the gonadal system and the obstructed lymphatics of the lower extremity. Preliminary experience in male dogs wherein lower extremity lymphedema is first induced surgically and is treated by testicular implantation into the edematous thigh shows that lympholymphatic communications between the lower extremity and the gonadal system may result.

Animals↗